Mineralys Therapeutics, Inc. (MLYS) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
MLYS currently has 82.4M outstanding shares. with moderate dilution risk from 19.4M authorized shares representing 23.5% potential dilution. The company has significantly diluted shareholders by 60.66% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Jun 03, 2026 |
8-K filing: Mineralys Therapeutics, Inc. announced the pricing of an underwritten public offering of 5,660,378 shares of its common stock at a public offering price of $26.50 per share. ($150.0M proceeds) |
82M | 19M |
| Mar 12, 2026 |
10-K filing | 82.4M shares outstanding |
82M | 19M |
| Nov 10, 2025 |
10-Q filing | 79.1M shares outstanding |
79M | 19M |
| Sep 03, 2025 |
8-K filing: Mineralys Therapeutics, Inc. entered into an underwriting agreement for the issuance and sale of 9,803,921 shares of common stock at $25.50 per share, with an option for the underwriters to purchase up to 1,470,588 additional shares. ($234.7M proceeds) |
65M | 19M |
| Aug 12, 2025 |
10-Q filing | 65.5M shares outstanding |
65M | 19M |
| May 12, 2025 |
10-Q filing | 65.2M shares outstanding |
65M | 19M |
| Mar 12, 2025 |
8-K filing: Mineralys Therapeutics, Inc. entered into an underwriting agreement for the issuance and sale of 12,962,962 shares of its common stock at a public offering price of $13.50 per share, with the offering expected to close on March 13, 2025. ($164.2M proceeds) |
49M | 19M |
| Feb 12, 2025 |
10-K filing | 48.5M shares outstanding |
49M | 19M |
| Nov 12, 2024 |
10-Q filing | 49.8M shares outstanding |
50M | 19M |
| Aug 13, 2024 |
10-Q filing | 49.4M shares outstanding |
49M | 19M |
| May 09, 2024 |
10-Q filing | 44.9M shares outstanding |
45M | 19M |
| Mar 29, 2024 |
S-3/A filing: This is an S-3/A filing that includes an ATM Equity Offering Sales Agreement, dated as of March 21, 2024, by and among Mineralys Therapeutics, Inc., BofA Securities, Inc. and Evercore Group L.L.C. |
41M | 19M |
| Mar 21, 2024 |
10-K filing | 49.6M shares outstanding |
50M | 19M |
| Mar 21, 2024 |
S-3 filing: The filing is an S-3 form for an at-the-market offering of common stock with an aggregate offering price of up to $100,000,000. The company intends to use the net proceeds for general corporate purposes. |
41M | 19M |
| Feb 08, 2024 |
8-K filing: Mineralys Therapeutics, Inc. entered into a securities purchase agreement for a private placement of 8,339,169 shares of common stock at $13.50 per share and pre-funded warrants to purchase 549,755 shares at $13.499 per warrant, with aggregate gross proceeds expected to be approximately $120 million before deducting offering expenses. |
40M | 12M |
| Nov 07, 2023 |
10-Q filing | 39.9M shares outstanding |
40M | 12M |
| Aug 07, 2023 |
10-Q filing | 39.8M shares outstanding |
40M | 12M |
| May 15, 2023 |
10-Q filing | 40.9M shares outstanding |
41M | 12M |
| Feb 02, 2023 |
S-1/A filing: This is an S-1/A filing for an initial public offering of common stock. |
27M | 12M |
| Jan 18, 2023 |
S-1 filing: This S-1 filing outlines the initial public offering of MLYS, detailing the common stock offering, potential underwriter options, use of proceeds, and associated risk factors. |
69M | 0 |